Johan Van Hoof

Medicine · Health Sciences

20h-index6.8kcitations48works11.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(19), COVID-19 Clinical Research Studies(12), Vaccine Coverage and Hesitancy(6), Animal Genetics and Reproduction(5), Virus-based gene therapy research(4)

Publications46 total

Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
UNC Libraries·2025Open Access
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial
The Lancet Infectious Diseases·2024· 29 citedOpen Access
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
npj Vaccines·2022· 20 citedOpen Access
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Infectious Diseases·2022· 84 citedOpen Access
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
Vaccine·2022· 32 citedOpen Access
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
New England Journal of Medicine·2022· 246 citedOpen Access
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19
2022· 6 citedOpen Access
LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
Open Forum Infectious Diseases·2021Open Access
Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
2021· 23 citedOpen Access
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
New England Journal of Medicine·2021· 252 citedOpen Access
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2021Open Access
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
2021· 20 citedOpen Access
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Nature·2021· 342 citedOpen Access
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
New England Journal of Medicine·2021· 2.5k citedOpen Access
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
JAMA·2021· 313 citedOpen Access
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine
Annals of Internal Medicine·2021· 76 cited
Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Nature·2021· 13 citedOpen Access
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
New England Journal of Medicine·2021· 1.2k citedOpen Access
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
2020· 141 citedOpen Access
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Nature·2020· 889 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Hanneke Schuitemaker(22), Macaya Douoguih(17), Dan H. Barouch(15), Mathieu Le Gars(14), Frank Struyf(14), Jerald Sadoff(13), Carla Truyers(12), Dirk Heerwegh(12), Anne Marit de Groot(10), Jinyan Liu(10), Georgi Shukarev(9), Gert C. Scheper(9), Abishek Chandrashekar(9), Jingyou Yu(9), Katherine McMahan(9), Kathryn E. Stephenson(8), F. Harrisson(8), Jenny Hendriks(7), Lisa H. Tostanoski(7), Caroline Atyeo(7)